Table 1 Clinicodemographic characteristics of the study population in each group at the time of blood culture
All patients (n = 173) | R group (n = 129) | Control group (n = 44) | P value | |
|---|---|---|---|---|
Percentage of patients | 100 | 74.6 | 25.4 | |
A: Resistant organism detected | 15 (9) | 15 (12) | 0 (0) | |
B: Antimicrobial use within 90 days | 108 (62) | 108 (84) | 0 (0) | |
C: Hospitalization within 90 days | 87 (50) | 87 (67) | 0 (0) | |
Age | 73 (63–81) | 75 (65–81) | 72 (58–77) | 0.042 |
Female sex | 69 (40) | 55 (43) | 14 (32) | 0.206 |
Body mass index | 22 (19–26) | 22 (19–25) | 24 (21–26) | 0.005 |
Coexisting condition | ||||
COPD | 11 (6) | 11 (9) | 0 (0) | 0.035 |
Diabetes | 67 (39) | 46 (36) | 21 (48) | 0.156 |
Dialysis | 10 (6) | 10 (8) | 0 (0) | 0.048 |
Malignancy | 36 (21) | 30 (23) | 6 (14) | 0.175 |
Allergy to antibiotics | 5 (3) | 3 (2) | 2 (5) | 0.376 |
Implantable devices | ||||
Endovascular device | 44 (25) | 42 (33) | 2 (5) | < 0.001 |
Artificial joint | 11 (6) | 11 (9) | 0 (0) | 0.035 |
Admission source | < 0.001 | |||
Emergency department | 92 (53) | 53 (41) | 39 (89) | |
General ward | 81 (46) | 76 (58) | 5 (11) | |
SOFA score | 8 (5–11) | 8 (5–11) | 7 (3–11) | 0.529 |
Δ SOFA score | 4 (1–8) | 4 (0–8) | 7 (3–11) | 0.006 |
Lactate (mmol/L) | 2.2 (1.3–3.9) | 2.1 (1.3–3.5) | 2.8 (1.3–4.9) | 0.101 |
Sepsis | 122 (70) | 84 (65) | 38 (86) | 0.008 |
Septic shock | 65 (37) | 48 (37) | 17 (38) | 0.866 |